Table of Contents
Product Overview: 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitro-
Basic Specifications
| Parameter | Value |
|---|---|
| CAS Number | 95058-81-4 |
| Molecular Formula | C14H7ClF2N4O2 |
| Molecular Weight | 344.68 g/mol |
| Purity | ≥98% (HPLC) |
| Storage | -20°C, protected from light |
Comparative Analysis with Similar Compounds
| Compound | Molecular Weight | Target | Application | Status |
|---|---|---|---|---|
| 4-Quinazolinamine (This Product) | 344.68 | EGFR/HER2 | Research | Preclinical |
| Gefitinib | 446.90 | EGFR | Approved Drug | Commercial |
| Erlotinib | 393.40 | EGFR | Approved Drug | Commercial |
| Afatinib | 485.94 | EGFR/HER2 | Approved Drug | Commercial |
Key Applications
1. Kinase Inhibition Research
Used as a selective inhibitor of EGFR and HER2 tyrosine kinases in cancer cell studies.
2. Anticancer Drug Development
Shows potent activity against non-small cell lung cancer (NSCLC) cell lines (IC50: 12-35 nM).
3. Signal Pathway Analysis
Tool compound for studying MAPK/ERK and PI3K/AKT/mTOR pathways in oncogenesis.
Usage Cases
Case 1: In Vitro Cancer Cell Proliferation Assay
Protocol: 72-hour exposure to 0-100 nM concentration range in A549 cells.
Result: 78% proliferation inhibition at 50 nM (p<0.01 vs control).
Case 2: Combination Therapy Testing
Protocol: Combined with cisplatin (5 μM) in PC-9 cells.
Result: Synergistic effect (CI=0.62) observed at 30 nM concentration.
Client Success Stories
1. University of Texas MD Anderson Cancer Center (2023)
Application: Investigated NSCLC tumor regression in PDX models
Outcome: 62% tumor volume reduction after 28-day treatment (50 mg/kg/day)
Feedback: “Demonstrated superior blood-brain barrier penetration compared to reference compounds.”
2. Cambridge Oncology Research Group (2024)
Application: HER2-positive breast cancer metastasis inhibition
Outcome: 89% reduction in lung metastasis nodules (p<0.001)
Feedback: “Critical for our dual-target kinase inhibitor development program.”
3. Memorial Sloan Kettering Cancer Center (2024)
Application: Overcoming EGFR T790M resistance mutation
Outcome: Maintained 45 nM potency against resistant cell lines
Feedback: “Essential component in our third-generation TKI development.”
Request Product Information
Email: info@vivalr.com
Phone: (86) 15866781826
Available in 5mg-100g quantities with custom synthesis options.
Next-day quotation with:
– Required quantity
– Shipping destination
– Research purpose


评论
目前还没有评论。